Topic 179 — Compulsory Licensing Comprehensive Framework

COMPULSORY LICENSING is the most powerful flexibility India has incorporated from TRIPS — the framework that allows the government to grant a license to a third party to exploit a patented invention WITHOUT THE PATENT HOLDER'S CONSENT, subject to specified conditions, when the public interest justifies. India's framework is among the most ROBUST + FLEXIBLE in the developing world. It draws strength from DOHA DECLARATION 2001 (Public Health) which affirmed TRIPS flexibility for affordable medicines, and the AUGUST 30, 2003 DECISION + ARTICLE 31bis (effective 23 January 2017 — India ratified) enabling export of compulsory-licensed medicines. The Indian framework operates under Sections 84-92, 92A, 92B Patents Act 1970, providing FOUR distinct grounds + three categories of compulsory licensing. SECTION 84 — STANDARD COMPULSORY LICENSING: any interested person may apply 3+ years after grant; THREE GROUNDS — (a) reasonable requirements of public not satisfied; (b) invention not available at reasonable price; (c) invention not worked in India. Decision by Controller of Patents. NATCO v. BAYER (2012) — first compulsory license; Nexavar/sorafenib cancer drug; Patent Office held all three grounds satisfied; 6% royalty rate; affirmed by IPAB and Bombay HC. SECTION 92 — NOTIFICATION COMPULSORY LICENSING: Central Government notification for circumstances of national emergency; circumstances of extreme urgency; public non-commercial use. SECTION 92A — EXPORT COMPULSORY LICENSING: India's 2005 implementation of Article 31bis WTO mechanism; export to countries with insufficient pharmaceutical manufacturing capacity. SECTION 92B — RECIPROCAL EXPORTS: between India + other developing countries. KEY GROUNDS: (1) Public health emergencies; (2) National security; (3) Anti-competitive practices remediation. Recent landmark cases: NATCO PHARMA v. BAYER (2012) — landmark first; BDR PHARMA v. BAYER (2013) — rejected; LEE PHARMA v. ASTRAZENECA (2015) — rejected. India's framework distinguishes from US (Bayh-Dole; restrictive); EU (more restrictive); Brazil + Thailand (similar to India); China + Indonesia. The framework integrates with: PATENTS ACT 1970; PATENTS RULES 2003 + 2024 AMENDMENTS; TRIPS Agreement Articles 31, 31bis; DOHA DECLARATION 2001; Article 27.3 + 31. KEY DEVELOPMENT: Compulsory licensing remains primarily THEORETICAL after 2012-2015 attempts — but represents critical NEGOTIATION LEVERAGE + STRATEGIC FLEXIBILITY. CCI Penalty Guidelines 2024 + IT Rules 2021 + DPDP Act 2023 + Section 3(d) anti-evergreening framework integration. This topic walks through every aspect of compulsory licensing — three sections + procedure + landmark cases + comparative frameworks + strategic considerations.

1. Compulsory Licensing Foundational Framework

A. International Foundation

✅ International Compulsory Licensing Framework

TRIPS FRAMEWORK: · TRIPS Article 31 — basic compulsory license framework. · TRIPS Article 31bis — export facility (effective 23 January 2017). · India ratified Article 31bis 2017. DOHA DECLARATION 2001: · "Doha Declaration on TRIPS Agreement and Public Health" (14 November 2001). · Affirms TRIPS flexibility for public health. · Each member determines emergency conditions. · Public health priority over commercial considerations. · Strengthens compulsory licensing legitimacy. AUGUST 30, 2003 DECISION: · WTO General Council decision. · Allowed compulsory licensing for export. · To countries with insufficient pharmaceutical capacity. · Implementation by member states. · Eventually codified as Article 31bis. KEY INTERNATIONAL ELEMENTS: · "Reasonable terms" requirement. · Adequate remuneration to patent holder. · Duration limited to need. · Subject to judicial review. · No discrimination by field of technology. INDIAN POSITION: · Strong supporter of TRIPS flexibilities. · South-South cooperation framework. · Public health priority. · Generic medicines access. · Strategic technology autonomy.

2. Section 84 — Standard Compulsory Licensing

A. Section 84 Framework

Section 84(1) Patents Act 1970

"84. Compulsory licences.—(1) At any time after the expiration of three years from the date of the grant of a patent, any person interested may make an application to the Controller for grant of compulsory licence on patent on any of the following grounds, namely:— (a) that the reasonable requirements of the public with respect to the patented invention have not been satisfied; or (b) that the patented invention is not available to the public at a reasonably affordable price; or (c) that the patented invention is not worked in the territory of India."

B. Three Distinct Grounds

✅ Section 84 — Three Distinct Grounds

GROUND 1: REASONABLE REQUIREMENTS NOT SATISFIED: · Public demand for invention. · Patent holder's production inadequate. · Lack of supply. · Quality concerns. · Distribution challenges. · Geographic accessibility. GROUND 2: NOT AVAILABLE AT REASONABLE PRICE: · Pricing analysis. · Affordability assessment. · Comparable products. · Public benefit consideration. · Generic alternatives. · International pricing benchmarks. GROUND 3: NOT WORKED IN INDIA: · Local manufacturing requirement. · "Working" interpretation. · Importation vs. local production. · Section 83 + 84 framework. · Government policy alignment. KEY ELIGIBILITY: · Any "interested person". · Generic manufacturers. · Civil society. · Other patent holders (cross-licensing). · State enterprises. ELIGIBILITY TIMING: · 3 years post-grant minimum. · Earlier in pharmaceutical emergency cases. ROYALTY DETERMINATION: · Reasonable royalty rate. · Comparable licensing rates. · Cost analysis. · Profit-sharing framework. NATCO-BAYER 2012 — 6% ROYALTY.

3. Natco v. Bayer 2012 — Landmark First Compulsory License

📖 Natco Pharma v. Bayer Corporation, 2012 (Patent Office; affirmed IPAB; affirmed Bombay HC 2014)

Background — Natco applied for compulsory license over Bayer's patent on Nexavar (sorafenib) for advanced kidney + liver cancer.

Bayer's Position — Patent grants exclusive market control; pricing is patent holder's prerogative; importing meets working requirement.

Patent Office Findings — Bayer's monthly cost ~₹2.8 LAKHS; Natco proposed ₹8,800/month (97% reduction).

Three Grounds Held Satisfied — (1) Reasonable requirements not satisfied (only 200 patients reached); (2) Not at reasonable price (₹2.8L vs ₹8.8K); (3) Not worked in India (imports only).

Ruling — Compulsory license granted to Natco; royalty 6% of sales.

IPAB Affirmation — Affirmed all three grounds + 6% royalty.

Bombay HC 2014 — Affirmed Patent Office + IPAB.

Significance — Foundational compulsory licensing precedent; pharmaceutical access framework.

International Impact — South-South cooperation; affordable medicines movement.

4. Section 92 — Government Compulsory Licensing

A. Section 92 Framework

Section 92(1) Patents Act 1970

"92. Special provision for compulsory licences on notifications by Central Government.—(1) If the Central Government is satisfied, in respect of any patent in force in circumstances of national emergency or in circumstances of extreme urgency or in case of public non-commercial use, that it is necessary that compulsory licences should be granted at any time after the sealing thereof to work the invention, it may make a declaration to that effect, by notification in the Official Gazette, and thereupon the following provisions shall have effect, that is to say,— (i) the Controller shall, on application made at any time after the notification by any person interested, grant to the applicant a licence under the patent on such terms and conditions as he thinks fit..."

B. Three Government Grounds

National Emergency.
Extreme Urgency.
Public Non-Commercial Use.

C. Section 92 Triggers

Public health epidemics (COVID-19 considered; not exercised).
National security crisis.
Natural disasters.
War + conflict situations.
Government research + procurement.
Strategic minerals + materials.

5. Section 92A — Export Compulsory Licensing

A. Section 92A Framework

Section 92A Patents Act 1970

"92A. Compulsory licence for export of patented pharmaceutical products in certain exceptional circumstances.—(1) Compulsory licence shall be available for manufacture and export of patented pharmaceutical products to any country having insufficient or no manufacturing capacity in the pharmaceutical sector for the concerned product to address public health problems, provided compulsory licence has been granted by such country or such country has, by notification or otherwise, allowed importation of the patented pharmaceutical products from India. (2) The Controller shall, on receipt of an application in the prescribed manner, grant a compulsory licence solely for manufacture and export of the concerned pharmaceutical product to such country under such terms and conditions as may be specified..."

B. Article 31bis Implementation

✅ Section 92A — Export Mechanism

BACKGROUND: · India's 2005 implementation of Article 31bis WTO mechanism. · Allows export of compulsorily-licensed medicines. · To countries with insufficient pharmaceutical capacity. · Public health emergency response. ELIGIBILITY: · Importing country must have: - Granted compulsory license OR - Notified WTO of importation framework. · Specific product framework. · Specific quantity framework. · Specific patient population. PROCESS: · Indian generic manufacturer applies. · Specific export quantity. · Importing country verification. · Anti-diversion measures. · Specific labelling requirements. KEY CASES: · Limited Indian export practice. · South-South pharmaceutical cooperation. · India's "pharmacy of the world" role. · COVID-19 vaccine framework. IMPACT: · Major pharmaceutical export potential. · Strategic developing country support. · Foreign relations dimension. · Generic manufacturing strength. INTERNATIONAL FRAMEWORK: · Doha Declaration 2001. · August 30, 2003 Decision. · Article 31bis (effective 2017). · India ratified. · Most LDCs eligible. · Health-related TRIPS framework.

6. Compulsory Licensing Procedure

A. Step-by-Step Procedure

✅ Compulsory Licensing Procedure Workshop

STEP 1 — APPLICATION: · Applicant identifies grounds. · Section 84 / 92 / 92A. · Form 17 (or Form 14 for Section 92). · Detailed grounds + evidence. · Proposed terms + royalty. STEP 2 — CONTROLLER EXAMINATION: · Section 84(1) grounds verification. · Application disclosure. · Patent holder notification. · Patent holder response opportunity. STEP 3 — HEARING: · Controller hearing both parties. · Evidence + arguments. · Industry expert testimony. · Public health advocate input. STEP 4 — CONTROLLER DECISION: · Grounds verification. · Royalty determination. · Specific terms + conditions. · Duration framework. STEP 5 — IPAB / HC IPD APPEAL: · Patent holder appeal. · Applicant appeal. · IPAB jurisdiction (now to HC IPD). STEP 6 — IMPLEMENTATION: · License agreement framework. · Royalty payment. · Manufacturing scale-up. · Quality compliance. · Anti-diversion. KEY ELEMENTS: · Reasonable royalty rate. · Adequate remuneration. · Specific scope of license. · Duration limited. · Termination conditions. · Quality standards. · Export restrictions. DOCUMENTATION: · Detailed application + grounds. · Patent details. · Pricing analysis. · Public health evidence. · Comparable licensing data. · Local manufacturing capability.

7. Subsequent Cases + Industry Trends

A. BDR Pharma v. Bayer 2013 — Rejected

📖 BDR Pharma v. Bayer, 2013 (Patent Office)

Background — BDR applied for compulsory license over Bayer's sorafenib patent (separate from Natco license).

Holding — Application REJECTED.

Reasons — BDR did not negotiate with Bayer adequately; failed to attempt voluntary license.

Significance — Demonstrates need for genuine prior negotiation; contrast with Natco approach.

B. Lee Pharma v. AstraZeneca 2015 — Rejected

📖 Lee Pharma v. AstraZeneca, 2015 (Patent Office)

Background — Lee Pharma applied for compulsory license over AstraZeneca's saxagliptin patent.

Holding — Application REJECTED.

Reasons — Lee Pharma failed to negotiate with AstraZeneca; insufficient evidence of unmet need.

Significance — Reaffirms Section 84 grounds + procedure rigor.

C. COVID-19 Considerations

COVID-19 pandemic raised compulsory licensing discussions.
India did NOT formally invoke Sections 92, 92A, 84.
Voluntary license + Trade-Related cooperation.
Vaccine pricing + procurement framework.
Future emergency framework strengthened.

8. Comparative Compulsory Licensing

A. Comparative Frameworks

Country	CL Framework	Notable Cases
India	Section 84 + 92 + 92A + 92B	Natco-Bayer 2012; subsequent rejections.
Brazil	Strong CL framework	Efavirenz 2007 — first major case.
Thailand	Used since 2007	Various HIV + cancer drugs.
South Africa	Limited CL use	Section 4 NRDC framework.
Canada	Section 23-25 Patent Act	Limited use.
US	Bayh-Dole + 35 USC § 271	Restrictive use; mostly state.
EU	Compulsory License Regulation	Limited; refusal to deal framework.
China	Patent Law Article 49	Limited use; competitive concerns.

9. Strategic Considerations

✅ For compulsory licensing strategy — eight points

For applicants, demonstrate genuine prior negotiation effort.

For patent holders, structure pricing + access programs proactively.

For developing country imports, leverage Section 92A framework.

For public health emergencies, monitor Section 92 framework.

For pharmaceutical access, document affordability evidence.

For local manufacturing, leverage Section 84(c) "working" requirement.

For strategic negotiation, leverage compulsory licensing leverage.

For international cooperation, leverage Doha + Article 31bis frameworks.

10. Memory Aid — Quick Recall

✅ Quick Recall — Compulsory Licensing

TRIPS Article 31 + 31bis (effective 23 January 2017; India ratified).

Doha Declaration 2001 — Public Health flexibility.

August 30, 2003 Decision — Export framework.

Section 84 — three grounds (reasonable requirements + reasonable price + worked in India).

Section 84 — 3 years post-grant minimum.

Section 92 — Government notification (national emergency + extreme urgency + public non-commercial).

Section 92A — Export to countries with insufficient capacity.

Section 92B — Reciprocal exports.

Natco v. Bayer 2012 — landmark first; 6% royalty; Nexavar.

BDR Pharma 2013 — REJECTED (no prior negotiation).

Lee Pharma 2015 — REJECTED (insufficient evidence).

COVID-19 — voluntary + Trade-Related framework.

🎯 EXAM POINTERS — TOPIC 179

TRIPS Article 31 — basic compulsory license framework.
TRIPS Article 31bis — export facility (effective 23 January 2017).
India ratified Article 31bis 2017.
Doha Declaration on TRIPS Agreement and Public Health (14 November 2001).
August 30, 2003 WTO General Council Decision — export framework.
Section 84 Patents Act 1970 — Standard Compulsory Licensing.
Section 84(1) — three grounds.
Section 84(1)(a) — reasonable requirements of public not satisfied.
Section 84(1)(b) — invention not available at reasonable price.
Section 84(1)(c) — invention not worked in India.
Section 84 — 3 years post-grant minimum eligibility.
Section 92 — Government Notification Compulsory Licensing.
Section 92 grounds: National Emergency + Extreme Urgency + Public Non-Commercial Use.
Section 92A — Export Compulsory Licensing for pharmaceutical products.
Section 92A — to countries with insufficient pharmaceutical manufacturing capacity.
Section 92B — Reciprocal Exports between developing countries.
Natco Pharma v. Bayer Corporation (2012 Patent Office; IPAB; Bombay HC 2014).
Natco-Bayer — Nexavar (sorafenib) for kidney + liver cancer.
Natco-Bayer — Bayer ₹2.8 LAKHS/month vs Natco ₹8,800/month (97% reduction).
Natco-Bayer — All three Section 84(1) grounds satisfied.
Natco-Bayer — 6% royalty rate set.
Natco-Bayer — Foundational compulsory licensing precedent.
BDR Pharma v. Bayer (2013 Patent Office) — REJECTED for inadequate negotiation.
Lee Pharma v. AstraZeneca (2015 Patent Office) — REJECTED for insufficient evidence.
Form 17 — Section 84/92 application.
Form 14 — Section 92 framework.
IPAB → HC IPD appeal framework (post Tribunals Reforms Act 2021).
Reasonable royalty rate determination.
Adequate remuneration to patent holder.
Section 90 — terms + conditions framework.
Section 91 — license to be assigned.
Comparable Brazil + Thailand frameworks.
COVID-19 — India did NOT formally invoke Sections 84/92/92A.